Levobunolol
From Wikipedia, the free encyclopedia
|
Levobunolol
|
|
| Systematic (IUPAC) name | |
| 5-(2-hydroxy-3-tert-butylamino-propoxy) tetralin-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H25NO3 |
| Mol. mass | 291.385 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Levobunolol is a beta blocking agent.
[edit] External links
- Ishibashi T, Yokoi N, Kinoshita S (2003). "Comparison of the effects of topical levobunolol and timolol solution on the human ocular surface.". Cornea 22 (8): 709–15. doi:. PMID 14576520.
- Ogasawara H, Yoshida A, Fujio N, Konno S, Ishiko S (1999). "[Effect of topical levobunolol on retinal, optic nerve head, and choroidal circulation in normal volunteers]". Nippon Ganka Gakkai Zasshi 103 (7): 544–50. PMID 10443129.
- Leung M, Grunwald J (1997). "Short-term effects of topical levobunolol on the human retinal circulation.". Eye 11 ( Pt 3): 371–6. PMID 9373479.
|
||||||||||||||||||||

